The Future of HNSCC: Aligning Teams, Transforming Care
About this episode
Experts discuss the future of treatment for locally advanced head and neck squamous cell carcinoma, focusing on trial data and team coordination.
Faculty: Ravindra Uppaluri, MD, PhD Faculty: Nancy Lee, MD, FASTRO This activity reviews data from the KEYNOTE-689 and NIVOPOSTOP trials evaluating perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Experts examine trial design, efficacy outcomes, and the role of PD-L1 combined positive score (CPS) in patient selection. Drs. Uppaluri and Lee discuss how surgical, medical, and radiation oncology teams can coordinate treatment sequencing and integrate perioperative pembrolizumab into practice for patients with locally advanced HNSCC.
More episodes of CME
- Counseling Patients on Their Future with Biologics
- Safety in oHCM Therapy: How and When to Transition Treatment?
- Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
- Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
- Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
- Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Explore listener stats, chart rankings, contacts and more on the CME podcast page.